LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABT

133.82

-0.01%↓

AZN

67.28

-4.02%↓

Search

AbbVie Inc

Aperta

SettoreSettore sanitario

189.09 3.47

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

181.55

Massimo

187.91

Metriche Chiave

By Trading Economics

Entrata

-1.6B

3M

Vendite

-1.8B

13B

P/E

Media del settore

84.816

54.379

EPS

2.46

Rendimento da dividendi

3.31

Margine di Profitto

0.02

Dipendenti

55,000

EBITDA

3.2B

3.7B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+14.63% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.31%

2.55%

Utili prossimi

24 lug 2025

Prossima data del Dividendo

15 mag 2025

Prossima data del' Ex Dividendo

14 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

7.8B

351B

Apertura precedente

185.62

Chiusura precedente

189.09

Notizie sul Sentiment di mercato

By Acuity

24%

76%

59 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

AbbVie Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 apr 2025, 13:57 UTC

Utili

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 apr 2025, 12:52 UTC

Utili

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 apr 2025, 18:18 UTC

I principali Market Mover

Pharma Shares Reverse Losses After Tariff Pause

9 apr 2025, 09:39 UTC

I principali Market Mover

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27 feb 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 feb 2025, 13:41 UTC

I principali Market Mover

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

7 mag 2025, 09:30 UTC

Notizie principali

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 apr 2025, 12:44 UTC

Utili

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 apr 2025, 09:33 UTC

Utili

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr 2025, 16:03 UTC

Utili

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr 2025, 14:00 UTC

Notizie principali
Utili

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr 2025, 12:24 UTC

Notizie principali
Utili

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr 2025, 12:03 UTC

Notizie principali
Utili

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q Net $1.29B >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q EPS 72c >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q Adj EPS $2.46 >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie 1Q Rev $13.34B >ABBV

25 apr 2025, 11:43 UTC

Utili

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 mar 2025, 09:30 UTC

Notizie principali

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 mar 2025, 15:04 UTC

Acquisizioni, Fusioni, Takeovers

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 feb 2025, 12:00 UTC

Notizie principali

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb 2025, 13:25 UTC

Notizie principali
Utili

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Utili

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 feb 2025, 12:00 UTC

Notizie principali

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 gen 2025, 15:50 UTC

Notizie principali
Utili

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

Confronto tra pari

Modifica del prezzo

AbbVie Inc Previsione

Obiettivo di Prezzo

By TipRanks

14.63% in crescita

Previsioni per 12 mesi

Media 215.6 USD  14.63%

Alto 250 USD

Basso 194 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbbVie Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

14

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

180.37 / 195.54Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

59 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.